Mounjaro Kidney Disease UK - Safety & Dosing from £124.99

Clinically Proven UK Registered Pharmacy

Mounjaro Kidney Disease Safety - From £124.99

Mounjaro from £124.99 with renal safety review, £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro and Kidney Disease: Safety, Efficacy and Renal Protection in the UK

Published: 11 September 2026

Mounjaro kidney disease considerations are critical for patients with chronic kidney disease (CKD) seeking weight loss treatment. Tirzepatide, the active ingredient in Mounjaro, has demonstrated favourable renal outcomes in clinical trials, with no dose adjustment required for mild to moderate renal impairment[1]. Understanding how Mounjaro interacts with kidney function helps UK patients and prescribers make informed, safe treatment decisions.

How Mounjaro Kidney Disease Safety Has Been Established in Clinical Trials

Mounjaro kidney disease safety profiles have been rigorously evaluated across the SURPASS clinical trial programme, which included patients with varying degrees of renal impairment[1]. In SURPASS-4, participants with type 2 diabetes and established cardiovascular disease—many of whom had concurrent CKD—showed significant reductions in HbA1c and body weight without adverse renal events[2]. Tirzepatide's dual GIP/GLP-1 receptor agonism does not rely on renal clearance for elimination, which is a key advantage over some other diabetes medications.

Post-hoc analyses from SURPASS trials revealed that tirzepatide reduced urinary albumin-to-creatinine ratio (UACR), a marker of kidney damage, by up to 30% compared to placebo[1]. This albuminuria reduction suggests potential renoprotective effects beyond glycaemic control. Patients with baseline eGFR ≥30 mL/min/1.73m² tolerated tirzepatide well, with no clinically meaningful decline in kidney function over 40–52 weeks of treatment[2]. These findings underpin current UK prescribing confidence for Mounjaro in patients with mild to moderate CKD.

At Cured Pharmacy, every Mounjaro prescription begins with a comprehensive online clinical assessment by a UK-registered prescriber, including renal function review. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all dispensed tirzepatide prescriptions align with MHRA guidance and individual patient safety profiles. Mounjaro is available from £124.99, subject to prescriber approval.

Mounjaro Kidney Disease Dosing: Adjustments for Renal Impairment

One of the most clinically relevant aspects of Mounjaro kidney disease management is that no dose adjustment is required for patients with mild (eGFR 60–89 mL/min/1.73m²) or moderate (eGFR 30–59 mL/min/1.73m²) renal impairment[1]. The standard titration schedule—starting at 2.5 mg subcutaneously once weekly and escalating every four weeks to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg—remains unchanged for these patient groups. This simplifies prescribing and reduces the risk of dosing errors in primary care.

For patients with severe renal impairment (eGFR 15–29 mL/min/1.73m²) or end-stage renal disease (ESRD), clinical experience with tirzepatide is limited, and the Summary of Product Characteristics advises caution[1]. In these cases, UK prescribers typically conduct a thorough risk-benefit assessment, considering alternative weight loss therapies such as semaglutide (Wegovy) or liraglutide (Saxenda), which also have established safety data in CKD populations. Mounjaro is not recommended for patients on dialysis until further evidence emerges.

Cured Pharmacy's clinical team reviews eGFR and creatinine values as part of the mandatory online consultation. If renal function falls outside safe prescribing thresholds, our prescribers will discuss alternative options or recommend liaison with the patient's GP or nephrologist. This integrated approach ensures Mounjaro kidney disease prescribing remains evidence-based and patient-centred.

Monitoring Kidney Function During Mounjaro Treatment

UK prescribing guidelines recommend baseline renal function assessment before initiating Mounjaro, followed by periodic monitoring every 3–6 months, particularly in patients with pre-existing CKD[2]. Monitoring includes serum creatinine, eGFR, and UACR to detect any early signs of deterioration. Gastrointestinal side effects—nausea, vomiting, diarrhoea—can lead to dehydration and transient worsening of renal function; patients should be counselled on adequate hydration and when to seek medical advice[3].

Mounjaro Kidney Disease Benefits: Evidence for Renal Protection

Emerging data suggest that Mounjaro kidney disease outcomes may extend beyond safety to active renal protection. In pooled analyses of SURPASS trials, tirzepatide significantly reduced UACR—a validated surrogate marker for CKD progression—by approximately 27% compared to placebo and by 18% compared to insulin glargine[1]. This albuminuria reduction was independent of glycaemic control and weight loss, suggesting direct renoprotective mechanisms.

Proposed mechanisms include improved glomerular haemodynamics, reduced systemic inflammation, and favourable effects on blood pressure and lipid metabolism[2]. Tirzepatide's dual agonism of GIP and GLP-1 receptors may confer additive benefits: GLP-1 receptor activation reduces intraglomerular pressure, while GIP receptor engagement enhances insulin sensitivity and lipid handling. These pathways collectively support kidney health in patients with obesity and type 2 diabetes.

The ongoing SURPASS-CVOT trial (cardiovascular outcomes trial) includes kidney endpoints as secondary measures, with results expected to provide definitive evidence on long-term renal outcomes[2]. Until then, UK clinicians rely on the consistent safety signals and albuminuria data from phase 3 trials to guide Mounjaro kidney disease prescribing. At Cured Pharmacy, we stay abreast of evolving evidence and update our clinical protocols accordingly.

Treatment Type Frequency Starting Price
Mounjaro (Tirzepatide) GIP/GLP-1 agonist injection Once weekly £145.00
Wegovy (Semaglutide) GLP-1 agonist injection Once weekly £89.00
Saxenda (Liraglutide) GLP-1 agonist injection Once daily £68.00
Orlistat Lipase inhibitor capsule Three times daily £32.00

Mounjaro Kidney Disease Contraindications and Precautions in the UK

While Mounjaro kidney disease safety is well-established for mild to moderate CKD, certain contraindications and precautions apply. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), regardless of renal function[1]. Severe gastrointestinal disease, including gastroparesis, warrants caution, as tirzepatide delays gastric emptying and may exacerbate symptoms.

Patients with diabetic ketoacidosis, type 1 diabetes, or hypersensitivity to tirzepatide should not use Mounjaro[1]. In the context of kidney disease, acute kidney injury (AKI) has been reported in association with severe dehydration secondary to gastrointestinal adverse effects[3]. UK prescribers must counsel patients to maintain hydration, recognise early symptoms of dehydration (dizziness, reduced urine output, dark urine), and seek prompt medical attention if these occur.

Concomitant use of other medications that affect renal function—such as NSAIDs, ACE inhibitors, or diuretics—requires careful monitoring. Mounjaro does not directly interact with these drugs, but the combined effects on fluid balance and blood pressure necessitate vigilance[3]. Cured Pharmacy's online consultation captures all concurrent medications and flags potential interactions for prescriber review.

When to Avoid Mounjaro in Kidney Disease Patients

Mounjaro should be avoided in patients with eGFR <15 mL/min/1.73m² or those requiring dialysis, due to insufficient clinical data in this population[1]. Pregnant or breastfeeding women with CKD should not use Mounjaro, as tirzepatide has not been studied in these groups and animal studies suggest potential foetal risk[1]. Any patient experiencing unexplained, persistent abdominal pain should discontinue Mounjaro and undergo evaluation for pancreatitis, which, although rare, has been reported with GLP-1 receptor agonists[3].

Comparing Mounjaro Kidney Disease Safety with Other Weight Loss Treatments

When evaluating Mounjaro kidney disease safety, UK prescribers often compare it with semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda), both GLP-1 receptor agonists with established renal safety profiles. Semaglutide, like tirzepatide, requires no dose adjustment for mild to moderate renal impairment and has demonstrated albuminuria reduction in the SUSTAIN trials[4]. Liraglutide, approved for weight loss as Saxenda, similarly shows renal safety in CKD patients, though its once-daily injection schedule and lower weight loss efficacy may be less appealing.

Tirzepatide's dual receptor agonism may offer superior weight loss and glycaemic control compared to single GLP-1 agonists, with SURPASS-2 showing 15% average weight loss at the 15 mg dose versus 5.7% with semaglutide 1 mg[2]. This enhanced efficacy is particularly relevant for obese patients with CKD, where weight reduction can independently improve renal outcomes. However, head-to-head renal endpoint data are lacking, and choice of therapy should be individualised.

Orlistat (Xenical, Alli) is another weight loss option, but its gastrointestinal side effects and modest efficacy (3–5% weight loss) make it less suitable for patients needing substantial weight reduction[4]. Orlistat is not contraindicated in CKD but offers no renoprotective benefits. At Cured Pharmacy, our prescribers discuss all licensed options—Mounjaro, Wegovy, Saxenda, and orlistat—tailoring recommendations to each patient's renal function, weight loss goals, and tolerability.

Accessing Mounjaro Kidney Disease Treatment at Cured Pharmacy

Cured Pharmacy is a UK-registered online pharmacy (GPhC 9012511) offering Mounjaro from £124.99, subject to clinical approval. Our streamlined online consultation takes under three minutes and includes mandatory questions on renal function, concurrent medications, and medical history. A UK-registered prescriber reviews every submission, ensuring Mounjaro kidney disease prescribing aligns with MHRA and NICE guidelines.

If your eGFR is ≥30 mL/min/1.73m² and you have no contraindications, you may be eligible for Mounjaro treatment. Patients with severe renal impairment or ESRD will be advised of alternative therapies or referred back to their GP or specialist. We provide 100% discreet packaging, next-day delivery options, and transparent pricing with no hidden fees. New patients receive £20 off their first order with code Weightlossnew.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical governance, ensuring every Mounjaro prescription meets the highest UK pharmacy standards. For questions about Mounjaro kidney disease suitability, call our team on (+44) 116 4646009 or complete the online assessment to receive personalised advice from a qualified prescriber.

Why Choose Cured Pharmacy for Mounjaro

Cured Pharmacy guarantees the lowest UK prices for genuine, MHRA-licensed Mounjaro. Unlike some online providers, we display pricing upfront—no consultation fees, no surprise charges. Our clinical team includes experienced prescribers who understand the nuances of Mounjaro kidney disease management, providing safe, evidence-based care. Start your assessment today to see if Mounjaro is right for you.

Scientific References

  1. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. [accessed 11 September 2026]
  2. Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., & Wiese, R. J. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10313), 1811–1824. [accessed 11 September 2026]
  3. National Institute for Health and Care Excellence. (2024). Tirzepatide for treating type 2 diabetes. NICE Technology Appraisal Guidance [TA924]. [accessed 11 September 2026]
  4. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. [accessed 11 September 2026]
  5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
  6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
  7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Is Mounjaro safe for patients with kidney disease?
Mounjaro is safe for patients with mild to moderate chronic kidney disease (eGFR ≥30 mL/min/1.73m²) and requires no dose adjustment. Patients with severe renal impairment should consult a prescriber for individualised assessment.
Does Mounjaro kidney disease treatment require dose changes?
No dose adjustment is needed for Mounjaro in patients with eGFR ≥30 mL/min/1.73m². The standard titration schedule from 2.5 mg to 15 mg applies to mild and moderate CKD patients.
Can Mounjaro improve kidney function?
Clinical trials show Mounjaro reduces albuminuria (a marker of kidney damage) by up to 30%, suggesting potential renoprotective effects beyond weight loss. Long-term renal outcomes are under investigation.
What kidney tests are needed before starting Mounjaro?
UK prescribers require baseline serum creatinine, eGFR, and urinary albumin-to-creatinine ratio (UACR) before initiating Mounjaro. Periodic monitoring every 3–6 months is recommended during treatment.
Can I use Mounjaro if I'm on dialysis?
Mounjaro is not recommended for patients on dialysis or with eGFR <15 mL/min/1.73m² due to limited clinical data. Discuss alternative weight loss options with your nephrologist and prescriber.
How does Mounjaro compare to Wegovy for kidney disease patients?
Both Mounjaro and Wegovy are safe in mild to moderate CKD with no dose adjustment required. Mounjaro's dual GIP/GLP-1 action may offer greater weight loss, but individual response varies.
What are the side effects of Mounjaro in kidney disease patients?
Common side effects include nausea, vomiting, and diarrhoea, which can cause dehydration and temporary worsening of kidney function. Patients should maintain hydration and report persistent symptoms promptly.
Where can I buy Mounjaro for kidney disease management in the UK?
Cured Pharmacy offers Mounjaro from £124.99 with a free online consultation and UK prescriber review. All patients undergo renal function assessment to ensure safe prescribing. Start your assessment at curedpharmacy.com.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 11 September 2026

Last updated on 11 September 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 11 September 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (11 September 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.